We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current CDMO market cap is 794.42M. The company's latest EPS is USD -2.2005 and P/E is -5.64.
| Quarter End | Jul 2023 | Oct 2023 | Jan 2024 | Apr 2024 | Jul 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 37.73M | 25.4M | 33.82M | 42.98M | 40.17M |
| Operating Income | -2.16M | -11.22M | -4M | -1.29M | -2.46M |
| Net Income | -2.09M | -9.51M | -6.05M | -123.1M | -5.53M |
| Year End 30 April 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 59.7M | 95.87M | 119.6M | 149.27M | 139.91M |
| Operating Income | -10.94M | 12.24M | 15.42M | 3.6M | -18.68M |
| Net Income | -15.15M | 3.32M | 127.67M | 560k | -140.75M |
| Quarter End | Jul 2023 | Oct 2023 | Jan 2024 | Apr 2024 | Jul 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 442.34M | 454.64M | 455.23M | 336.56M | 334.64M |
| Total Liabilities | 251.74M | 270.97M | 275.06M | 275.67M | 276.01M |
| Total Equity | 190.6M | 183.68M | 180.17M | 60.89M | 58.64M |
| Year End 30 April 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 107.62M | 265.51M | 429.84M | 451.05M | 336.56M |
| Total Liabilities | 65.72M | 187.77M | 255.32M | 261.58M | 275.67M |
| Total Equity | 41.9M | 77.74M | 174.53M | 189.47M | 60.89M |
| Quarter End | Jul 2023 | Oct 2023 | Jan 2024 | Apr 2024 | Jul 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -278k | 5.82M | 9.7M | 10.95M | -3.68M |
| Investing | -14.11M | -21.44M | -26.11M | -31.81M | -1.31M |
| Financing | 748k | 8.15M | 8.23M | 20.07M | 266k |
| Year End 30 April 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 5.83M | 31.18M | 9.47M | -12.89M | 10.95M |
| Investing | -3.81M | -9.86M | -56.41M | -77.64M | -31.81M |
| Financing | 1.1M | 112.34M | 3.2M | 2.9M | 20.07M |
| Market Cap | 794.42M |
| Price to Earnings Ratio | -5.64 |
| Price to Sales Ratio | 5.68 |
| Price to Cash Ratio | 20.85 |
| Price to Book Ratio | 13.05 |
| Dividend Yield | - |
| Shares Outstanding | 63.96M |
| Average Volume (1 week) | 1.57M |
| Average Volume (1 Month) | 1.44M |
| 52 Week Change | 82.11% |
| 52 Week High | 12.48 |
| 52 Week Low | 5.90 |
| Spread (Intraday) | 0.15 (1.2%) |
| Company Name | Avid Bioservices Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.peregrineinc.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
